QNCX Insider Trading
Insider Ownership Percentage: 16.80%
Insider Buying (Last 12 Months): $105,608.80
Insider Selling (Last 12 Months): $0.00
Quince Therapeutics Share Price & Price History
Current Price: $1.48
Price Change: ▼ Price Decrease of -0.18 (-10.84%)
As of 01/21/2025 05:00 PM ET
Quince Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/29/2024 | Dirk Thye | CEO | Buy | 77,500 | $0.69 | $53,475.00 | 766,941 |  |
| 8/21/2024 | Brendan Hannah | COO | Buy | 30,845 | $0.63 | $19,432.35 | 296,540 | |
| 8/20/2024 | Charles S Ryan | President | Buy | 48,387 | $0.65 | $31,451.55 | 122,461 | |
| 8/19/2024 | Brendan Hannah | COO | Buy | 2,155 | $0.58 | $1,249.90 | 259,771 | |
| 12/14/2023 | David Lamond | Director | Buy | 22,627 | $1.04 | $23,532.08 | 2,347,545 | |
| 12/12/2023 | David Lamond | Director | Buy | 22,327 | $1.02 | $22,773.54 | 2,302,291 | |
| 12/7/2023 | David Lamond | Director | Buy | 19,123 | $1.01 | $19,314.23 | 2,279,664 | |
| 12/5/2023 | David Lamond | Director | Buy | 19,123 | $1.01 | $19,314.23 | 2,241,418 | |
| 12/1/2023 | David Lamond | Director | Buy | 14,378 | $0.94 | $13,515.32 | 2,222,295 | |
| 11/29/2023 | David Lamond | Director | Buy | 14,378 | $0.98 | $14,090.44 | 2,193,539 | |
| 8/30/2023 | David Lamond | Director | Buy | 41,026 | $1.31 | $53,744.06 | 2,138,135 | |
| 8/17/2023 | David Lamond | Director | Buy | 24,766 | $1.29 | $31,948.14 | 2,097,109 | |
| 8/15/2023 | David Lamond | Director | Buy | 107,886 | $1.32 | $142,409.52 | 1,954,995 | |
| 8/10/2023 | Dirk Thye | CEO | Buy | 88,000 | $1.26 | $110,880.00 | 448,911 | |
| 8/8/2023 | Brendan Hannah | Insider | Buy | 71,762 | $1.22 | $87,549.64 | 201,555 | |
| 8/8/2023 | Dirk Thye | CEO | Buy | 80,000 | $1.24 | $99,200.00 | 360,911 | |
| 8/8/2023 | Margaret Mcloughlin | Director | Buy | 8,000 | $1.23 | $9,840.00 | 8,000 | |
| 3/6/2023 | Ted Monohon | CAO | Sell | 1,871 | $0.98 | $1,833.58 | 27,440 | |
Quince Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/16/2024 | Geode Capital Management LLC | 339,125 | $0.26M | 0.0% | +24.2% | 0.784% |  |
| 8/9/2024 | Renaissance Technologies LLC | 483,902 | $0.36M | 0.0% | -7.0% | 1.120% | |
| 1/12/2024 | Scharf Investments LLC | 91,061 | $96K | 0.0% | N/A | 0.212% | |
| 7/31/2023 | Intellectus Partners LLC | 53,527 | $81K | 0.0% | N/A | 0.148% | |
| 7/24/2023 | BML Capital Management LLC | 1,411,839 | $2.13M | 1.9% | N/A | 3.892% | |
| 5/11/2023 | EPIQ Capital Group LLC | 958,469 | $1.50M | 0.8% | -9.3% | 2.642% | |
| 4/20/2023 | Hennion & Walsh Asset Management Inc. | 31,061 | $48K | 0.0% | N/A | 0.086% | |
Data available starting January 2016
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More on Quince Therapeutics
Volume
280,671 shs
Average Volume
156,693 shs
Market Capitalization
$65.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.64
Who are the company insiders with the largest holdings of Quince Therapeutics?
